Diffusion of certain guidelines, addressing all of the elements of the use of LAI antipsychotics, will boost clinicians’ perceived competence. It can also help to raise the percentage of patients to whom LAI antipsychotics will probably be supplied by psychiatrists as a therapeutic solution. The objective of those guidelines is always to propose a prescription framework to clinicians for the use of a precise formulation of antipsychotics (LAI) in diverse therapeutic indications and specific clinical circumstances. The aim should be to allow clinicians to offer by far the most proper pharmaceutical approaches for the sufferers and to facilitate the usage of LAI antipsychotics in clinical practice. The recommendations presented here from a consensus-based recommendations methodology (Formal Consensus Guidelines) arebased on scientific data and also the consensus of a panel of professionals.MethodsQuestionnaire developmentInitially, we performed an evaluation and also a literature assessment concerning the indications and also the use of LAI antipsychotics. A literature search utilizing the keyword phrases “antipsychotic”, “neuroleptic”, “first-generation antipsychotic”, “atypical antipsychotic”, “second-generation antipsychotic”, “long-acting injectable”, “depot”, “depot neuroleptic” was performed in PubMed and EMBASE to discover all of the relevant studies published. Further references had been identified from http:www.fda.gov and http: www.ema.europa.eu. Information from all of these sources was discussed and an overview on the existing proof has been graded 
and summarized utilizing the French National Authority for Overall health (HAS) “levels of evidence” criteria [16]. Following this initial step, the scientific committee (PML, LS, MA, Pc, SG, SL) designed a questionnaire consisting of 32 concerns that covered 539 therapeutic selections. The 32 concerns had been regrouped into 3 places PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/21310042 that have been judged as vital: Target-population: Description of your distinctive indications in the LAI antipsychotics and with the most appropriate period of the illness to introduce the treatment. Prescription and use: Choice on the molecule, solutions of introduction, particular strategies depending on the psychiatric disorder or comorbidities, and therapy monitoring. Certain population: Use of LAI antipsychotics in pregnant women, elderly patients, subjects within a precarious situation, and subjects getting to be treated in a prison establishment. This questionnaire was made to be completed by an experts’ panel. The time MedChemExpress LJI308 required for its administration was estimated at about 3 hours. In the time of improvement, each of the LAI antipsychotics obtainable in France had been proposed as therapeutic possibilities (Table 1). They have been regrouped into 2 categories: Long-acting injectable first-generation antipsychotics (LAI FGA). Long-acting injectable second-generation antipsychotics (LAI SGA). This artificial separation FGASGA is not consensual as a consequence of their heterogeneous profiles of efficacyLlorca et al. BMC Psychiatry 2013, 13:340 http:www.biomedcentral.com1471-244X13Page 3 ofTable 1 LAI antipsychotics readily available in France (when the survey was completed)LAI second-generation antipsychotics LAI first-generation antipsychotics Risperidone microsphere Olanzapine pamoate Haloperidol decanoate Zuclopenthixol decanoate Flupentixol decanoate Fluphenazine decanoate Pipotiazine palmitateNote: as paliperidone palmitate had a marketing and advertising authorization date following the improvement of those guidelines, it couldn’t be taken into account.Specialist selectionThe Scientific Committee (Appendix 1) sel.